Last $5.74 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

celsus therapeutics-spon adr (CLTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/7/13 - $25.00
52 Week Low
04/15/14 - $4.63
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

celsus therapeutics-spon adr (CLTX) Related Businessweek News

No Related Businessweek News Found

celsus therapeutics-spon adr (CLTX) Details

Celsus Therapeutics Plc, a biopharmaceutical company, engages in the discovery and development of non-steroidal, synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs. The company’s products in Phase 2a clinical pipeline include MRX-4, a nasal spray for treating allergic rhinitis or hay fever, as well as MRX-6, a topical cream for treating contact dermatitis, a common type of eczema. Its product candidates in pre-clinical studies comprise OPT-1 for the treatment of conjunctivitis and dry eye; MRX-5 used in the treatment of inflammatory bowel disease; and CFX-1 for the treatment of cystic fibrosis. The company was formerly known as Morria Biopharmaceuticals Plc and changed its name to Celsus Therapeutics Plc in July 2013. Celsus Therapeutics Plc is headquartered in London, the United Kingdom.

4 Employees
Last Reported Date: 03/24/14

celsus therapeutics-spon adr (CLTX) Top Compensated Officers

Pre-Clinical Development Consultant
Total Annual Compensation: --
Compensation as of Fiscal Year 2012.

celsus therapeutics-spon adr (CLTX) Key Developments

Saul Yedgar Resigns from Board of Directors of Celsus Therapeutics PLC

On March 25, 2014, Saul Yedgar resigned from the board of directors of Celsus Therapeutics PLC due to personal reasons.

Celsus Therapeutics Plc Announces Earnings Results for the Year Ended December 31, 2013

Celsus Therapeutics Plc announced earnings results for the year ended December 31, 2013. The company's net loss for the year ended December 31, 2013 was $3.62 million, or a net loss per share of $0.17, compared to a net loss of $4.3 million or net loss per share of $0.35 at December 31, 2012.

Celsus Therapeutics Plc Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 03:40 PM

Celsus Therapeutics Plc Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 03:40 PM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Gur A. Roshwalb, Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLTX:US $5.74 USD 0.00

CLTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLTX.
View Industry Companies

Industry Analysis


Industry Average

Valuation CLTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELSUS THERAPEUTICS-SPON ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at